Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02429583 · ClinicalTrials.gov registry record · Phase 4
Effects of Persistent Innate Immune Activation on Vaccine Efficacy
A Phase 4 study, sponsored by Rockefeller University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT02429583 is a Phase 4 study that was terminated before completion, run by Rockefeller University. The registered enrollment target is 24 participants.
The verdict
NCT02429583, a Phase 4 study, was terminated before completion, sponsored by Rockefeller University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will investigate the effects of chronic HCV infection and corresponding innate immune activation on the immune response to HBV vaccination. We will recruit chronic HCV patients and healthy control patients for HBV vaccination. We will use RNA Sequencing (RNA-Seq), a relatively new technology for simultaneously measuring the expression of all genes, to determine patients' innate immune status, and learn how this innate immune signature is related to HBV vaccine response. We will then explore the mechanisms by which chronic HCV infection affects different immune cells and functions that are known to be important for an effective HBV vaccine response. These studies will enhance our understanding of the immune effects of chronic viral infection, establish factors that determine effective vaccine responses, and help guide vaccination strategies for HCV patients and other individuals with chronic inflammatory disease.
Interventions
- DRUG Recombivax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-05-08 |
| Est. Completion | 2018-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02429583
The ClinicalTrials.gov registry entry for NCT02429583 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockefeller University, which has 117 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Recombivax is the first listed.
NCT02429583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02429583 about?
NCT02429583 is a clinical study titled "Effects of Persistent Innate Immune Activation on Vaccine Efficacy". This study will investigate the effects of chronic HCV infection and corresponding innate immune activation on the immune response to HBV vaccination. We will recruit chronic HCV patients and healthy control patients for HBV vaccination. We will use RNA Sequencing (RNA-Seq), a relatively new technol...
What is the current status of trial NCT02429583?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2015-05-08. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02429583?
The interventions under investigation include: Recombivax (DRUG).
Who is sponsoring clinical trial NCT02429583?
This trial is sponsored by Rockefeller University, which has 117 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.